0001127602-16-065405.txt : 20161027
0001127602-16-065405.hdr.sgml : 20161027
20161027184456
ACCESSION NUMBER: 0001127602-16-065405
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20161025
FILED AS OF DATE: 20161027
DATE AS OF CHANGE: 20161027
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HAEMONETICS CORP
CENTRAL INDEX KEY: 0000313143
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042882273
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0328
BUSINESS ADDRESS:
STREET 1: 400 WOOD RD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
BUSINESS PHONE: 7818487100
MAIL ADDRESS:
STREET 1: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Burke Willaim P
CENTRAL INDEX KEY: 0001682069
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14041
FILM NUMBER: 161956607
MAIL ADDRESS:
STREET 1: HAEMONETICS CORPORATION
STREET 2: 400 WOOD ROAD
CITY: BRAINTREE
STATE: MA
ZIP: 02184
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2016-10-25
0000313143
HAEMONETICS CORP
HAE
0001682069
Burke Willaim P
400 WOOD ROAD
BRAINTREE
MA
02184
1
EVP, Chief Financial Officer
Common Stock
2016-10-25
4
A
0
10413
34.21
A
10413
D
Non-qualified Stock Option (Right to Buy)
34.21
2016-10-25
4
A
0
44926
34.21
A
2017-10-25
2023-10-25
Common Stock
44926
44926
D
Performance Shares
0
2016-10-25
4
A
0
20827
0
A
2019-09-30
2019-12-31
Common Stock
20827
20827
D
Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.
Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.
Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Share Unit based on the performance of Haemonetics stock price relative to the Total Shareholder Return of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600. The number of Performance Share Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2016 and September 30, 2019. The Performance Share Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Share Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).
/s/ Alexander P. Steffan, attorney-in-fact for Mr. Burke
2016-10-27